NCT00080678View on ClinicalTrials.gov

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

August 31, 2005

Study Completion Date

March 31, 2008

Conditions
Metastatic CancerProstate Cancer
Interventions
DRUG

Docetaxel

DRUG

Imatinib Mesylate

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00080678 - Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases | Biotech Hunter | Biotech Hunter